Table 2.
Severity grading of adverse events following mass IDA versus DA therapy for the control of lymphatic filariasis
| Type of event | IDA (n = 4868) | DA (n = 2865) | ||||
|---|---|---|---|---|---|---|
| Grade 1 (mild) | Grade 2 (moderate) | Grade 3 (severe) | Grade 1 (mild) | Grade 2 (moderate) | Grade 3 (severe) | |
| Fever | 298 (92.3%) | 23 (7.1%) | 2 (0.6%) | 218 (91.2%) | 21 (8.8%) | |
| Loss of appetite | 327 (95.3%) | 15 (4.4%) | 1 (0.3%) | 288 (92.3%) | 24 (7.7%) | |
| Dizziness | 1341 (85.2%) | 33 (13.5%) | 1 (0.4%) | 489 (88.9% | 60 (10.9%) | 1 (0.2%) |
| Confusion | 251 (90.9%) | 22 (8.0%) | 3 (1.1%) | 93 (94.9 %) | 5 (5.1%) | |
| Drowsiness | 892 (91.2%) | 83 (7.8%) | 3 (0.3%) | 222 (90.6%) | 23 (9.4%) | |
| Headache | 435 (91.4%) | 37 (7.8%) | 4 (0.8%) | 426 (80.4%) | 97 (18.3%) | 7 (1.3%) |
| Cough | 79 (81.4%) | 16 (16.5%) | 2 (2.1%) | 187 (89.9%) | 21 (10.1%) | |
| Difficulty breathing | 483 (88.9%) | 5 (9.3%) | 1 (1.9%) | 30 (81.1 %) | 7 (18.9%) | |
| Nausea | 222 (91%) | 21 (8.6%) | 1 (0.4%) | 163 (88.1%) | 21 (11.4%) | 1 (0.5%) |
| Vomiting | 183 (96.3%) | 7 (3.7%) | 144 (82.3 %) | 31 (17.7%) | ||
| Diarrhea | 93 (92.1%) | 8 (7.9%) | 86 (83.5 %) | 17 (16.5%) | ||
| Stomach pain | 184 (86.8%) | 26 (12.3%) | 2 (0.9%) | 156 (85.2 %) | 27 (14.8%) | |
| Total | 4353 (89.4%) | 489 (10.0%) | 26 (0.5%) | 2502 (87.3%) | 354 (12.4%) | 9 (0.3%) |
DA diethylcarbamnzine + albendazole, IDA ivermectin + diethylcarbazine + albendazole